April 18th 2024
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
Clinical Quiz: Nonstatin Therapies for LDL-C Lowering
March 25th 2024This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older
March 11th 2024Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.
Elevated Lp(a) Levels Linked to Cardiovascular Event Risk, Regardless of ASCVD History
March 4th 2024The latest analysis of the Mass General Brigham Lp(a) Registry highlights Lp(a)'s independent association with cardiovascular events, with these associations apparent in patients regardless of baseline cardiovascular history.
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
CLEAR Outcomes Analysis Finds Bempedoic Acid Reduces Total Cardiovascular Events by 20%
January 18th 2024In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.